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costs and outcomes discounted at 5%, equals 33,622 PLN 
(7815 €) for each year of life gained. CONCLUSIONS: In a pop-
ulation of high risk NSTEMI patients, adding eptiﬁbatide is a
cost-effective way of achieving health beneﬁts in terms of car-
diovascular events avoided, and ultimately life years saved. This
result is much below thresholds accepted in Poland (60,000
PLN—dialysis).
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COST-EFFECTIVENESS ANALYSIS OF THE USE OF
ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN
THE SECONDARY PREVENTION OF PATIENTS WITH
PREVIOUS MYOCARDIAL INFRACTION
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OBJECTIVES: To perform an economic evaluation of the use of
low dose acetylsalicylic acid (Adiro) in comparison with clopi-
dogrel (Plavix) in the prevention of cardiovascular events in
patients with a previous myocardial infarction (MI) using a cost-
effectiveness analysis in the setting of the Spanish National
Health Service. METHODS: Using the efﬁcacy data from the
CAPRIE study on the incidence of new cardiovascular events in
a group of patients with a previous MI, the sanitary and eco-
nomic consequences of the use of the two treatments, acetylsal-
icylic acid and clopidogrel, in this indication were modeled. The
costs used in this analysis refer to the year 2004 in the Spanish
National Health Service setting. RESULTS: In the base case, the
total cost of the acetylsalicylic acid treatment (€1515) was con-
siderably inferior to that of clopidogrel (€2942). The efﬁcacy
results in the subgroup of patients with a previous MI, are com-
paratively better with acetylsalicylic acid, however the difference
is not statistically signiﬁcant. With the assumptions adopted in
the base case, treatment with acetylsalicylic acid is superior
(better or equal efﬁcacy and less cost) when compared to treat-
ment with clopidogrel. The treatment with acetylsalicylic acid
was found to be superior to that of clopidogrel in all of the sce-
narios studied in the analysis of sensitivity. CONCLUSIONS:
The treatment with acetylsalicylic acid is effective, safe and cost-
effective in the secondary prevention of cardiovascular events 
in patients with a previous MI, and is still the ﬁrst choice
antiplatelet therapy for this indication.
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OBJECTIVE: to assess the economic and epidemiologic impact
of AMI in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst AMI hospital admis-
sion and we followed them up till death, or 31 Dec 2004 (we a
priory excluded people who during the period 1995–1999 had
a previous CHD event). Mortality was investigated by collecting
information from Regional Citizen Register ﬁle. We obtained
information on medical costs from electronic databases of pre-
scriptions, hospitalizations, visits and diagnostic examinations in
FVG. Direct medical costs were quantiﬁed in the perspective of
the RHS and are expressed in Euro 2005. RESULTS: We enrolled
1185 patients with incident AMI (mean age 71 ± 13 y.o.), 59%
were men. The average cost person/year was €4913.32; 71.2%
attributable to hospitalisations, 19.3% to drugs. The 38.5%
patients died during the follow up period, with a mean age of
79.3 ± 10.1 statistically different (p < 0.0001) from survivors
(mean age 65.0 ± 12.0 y.o.). There was no signiﬁcant difference
in mortality between men and women adjusting for age. CON-
CLUSIONS: AMI imposes a huge economic burden on NHS and
society because of the large number of hospitalisation and the
high rate of mortality after the ﬁrst event. Future investigations
will be conduct to asses the relationships between comorbidity,
costs, therapy and survival.
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OBJECTIVES: To measure the direct costs of selected cardio-
vascular diseases within the Austrian health care system for the
ﬁrst year including the event, as well as from the second year
onward. METHODS: In this study, we analyzed the direct costs
of angina pectoris (AP) and myocardial infarction (MI) in
Austria. The direct costs were identiﬁed as resource consump-
tion for hospitalization, inpatient rehabilitation, outpatient treat-
ment, medication and transportation. Costs for inpatient care
were calculated according to the tariffs of the Austrian Diagno-
sis Related Group (DRG) system and the average number of allo-
cated points to AP and MI. Costs for inpatient rehabilitation
treatment were calculated with tariffs per day taken into account
the mean duration of stay. For outpatient treatment costs we con-
sidered the average number of consultations and the fee for
service, which is mainly paid by social insurance. Medication
costs were calculated and assessed with tariffs according to the
distribution of type and amount of prescribed agents. Costs for
transportation after the event were included with the tariffs per
ride. RESULTS: The total costs for the treatment of MI in the
ﬁrst year of event in 2004 were calculated with €8.960, rehabil-
itation contributing to 68% of this amount. Since there were no
inpatient rehabilitation costs to consider from the second year
onward, costs declined to approximately €1.490 per year. Costs
due to AP amounted about €2.180 for the ﬁrst year and declined
on average to €1.190 from the second year onward. CONCLU-
SIONS: In line with the study direct costs for cardiovascular dis-
eases were calculated for the ﬁrst time in Austria. As one of the
main ﬁnding we would like to point out the high direct inpatient
rehabilitation costs as the main cost driving factor for MI in the
ﬁrst year of event.
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OBJECTIVES: To assess the efﬁcacy of cardiac rehabilitation
with a mixed primary and cardiological care program in patients
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with low-risk myocardial infarction. METHODS: The partici-
pants in this 12-month prospective study were 153 consecutive
patients with low-risk myocardial infarction (MI) referred to
their primary care center for follow-up care. Of these patients,
113 were referred to a mixed primary and specialized care
program that included physical exercise, cardiovascular risk
control, an antismoking program, health education talks and
psychological evaluation. The other 40 patients served as con-
trols. We analyzed the results after three months and 1 year of
follow-up. RESULTS: There were no differences between the two
groups at baseline. After 1 year, improvements were seen in
smoking habit (4.6% vs. 15.6%; P < 0.05) and body mass index
(26 [2] vs. 29 [2]; P < 0.05). Dyslipidemia, glucose and blood
pressure were similar in both groups after follow-up. Greater
improvements in the group of patients who participated in the
program were seen after 1 year in quality of life (78 [2] vs. 91
[2]; P < 0.05), exercise capacity (10.3 [2] vs. 8.4 [3]; P < < 0.01)
and return to active employment (84.6% vs. 53.3%; P < 0.05).
CONCLUSIONS: After one year of follow-up, the cardiac reha-
bilitation program coordinated by cardiological and primary
care services for low-risk post-MI patients improved quality of
life, and increased exercise tolerance, active employment, and the
number of participants who quit smoking. The mixed program
also reduced body mass index. These results suggest the need for
similar programs.
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OBJECTIVE: To estimate the direct medical costs in patients at
high risk that suffered an atherotrombotic event (AE), i.e., the
cost of the acute event and the costs related to the disease during
a two year follow up period in patients with myorcardial infarc-
tion and stroke, treated in third care level in private institutions
in the Mexican Health System. METHODS: This is a descrip-
tive observational and multicentric study. Each patient included
in the study cohort has an active medical ﬁle with a complete
record for at least a 2-year period after the AE. This study is
based on an incidence costing approach and only includes the
perspective of the payments. The unitary costs used are those
ofﬁcially published by private institutions. All the amounts are
set in 2005 Mexican pesos. The 2005 exchange rate is 11
Mexican pesos per US dollar. RESULTS: A patient who experi-
ences a stroke stays at least 5 days in Intensive Care. The
expected cost per treated patient with stroke reaches US$7876.
The most important category of cost during the acute phase is
hospitalization (US$3924; 50%). On the other hand, the total
direct cost incurred per patient with acute coronary syndrome
(ACS) is US$3367 per year of follow-up and US$16,381 in the
acute event. The most relevant costs are both pharmacy costs
(US$2354) and revascularization procedures (US$9319). Coro-
nary artery stent implantation is the most common revascular-
ization procedure (70%). CONCLUSIONS: AE are associated
with high costs during the years after the acute event, in special
high incidence of hospitalization and drug cost. These results,
especially the proportions between cost items, are consistent with
international studies. Effective prevention and treatment of AE
should be targeted not only on patients and medical profession-
als but also on health decision makers.
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OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual (DDD or DDDR) vs. single
chamber ventricular pacemaker (VVI or VVIR). METHODS: A
discrete event simulation was constructed to evaluate the out-
comes over ﬁve years. During the simulation, each patient may
develop post-operative complications, severe pacemaker syn-
drome leading to replacement of the VVI(R) with DDD(R), atrial
ﬁbrillation (which may become chronic and require anticoagu-
lants), or have a stroke. A time for each event is sampled from
the distribution of failure times speciﬁed by the individual’s risk
proﬁle. Life expectancy was estimated and assumed the same
with either device. Model risk functions are based on long-term
randomized trials (Canadian Trial of Physiological Pacing and
Mode Selection Trial in Sinus-Node Dysfunction). Probabilistic
sensitivity analyses were performed for key input parameters.
Direct medical costs are reported in 2004 Euros (€). Beneﬁts and
costs are discounted at 3% per year. RESULTS: Chronic atrial
ﬁbrillation was estimated to be 24% lower with DDD(R). Dis-
counted costs over 5 years were about €10,000 per patient in
either cohort, mean net additional cost of €106 with DDD(R).
DDD(R) led to 0.09 additional QALY; a mean cost-effectiveness
ratio of €1177/QALY, with 21% of replications indicating dom-
inance for DDD(R). Severe pacemaker syndrome requiring
switch to DDD(R) occurred in 16.8% with VVI(R); the results
are sensitive to the proportion that would seek replacement.
CONCLUSION: Lower initial costs with VVI(R) were offset by
second operations to switch to DDD(R) and costs of atrial ﬁb-
rillation. Thus, dual chamber pacemakers are economically
attractive in management of patients with bradycardia.
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OBJECTIVES: To evaluate short-term cost-effectiveness (cost-
utility) of cilostazol for the treatment of intermittent claudica-
tion from the perspective of the Scottish NHS. METHODS: A
decision analytic model was constructed and analysed from the
perspective of the Scottish NHS. Costs include direct medical
costs including drug costs -evaluated at retail prices excluding
taxes, and treatment costs. Treatment costs included the cost of
primary and specialist care of intermittent claudication patients
based on an independent survey of expert clinical opinion in
Scotland. Short- term effectiveness was based on two published
24 week randomised clinically controlled trials of cilostazol 
(100mg) versus placebo. Placebo was chosen as the comparator
since the majority of patients in Scotland do not currently receive
intermittent claudication- speciﬁc medical treatment. Health-
related quality of life was measured in the trials using the SF-36;
these scores were translated into utilities using a validated
mapping algorithm. QALYs were estimated over various scenar-
ios including the base-case analysis of the most conservative
assumption of immediate return to placebo utility post treat-
ment. RESULTS: The incremental cost- utility ratio for cilosta-
zol over placebo was estimated at approximately £12,500 per
QALY. The data were not discounted due to the short time
